Pierre A. MORGON joined us at the World Vaccine Congress today to give a perspective on the global vaccine market. He received his Doctorate of Pharmacy from the University of Lyon in 1985, his Masters in Business Law from the Lyon Law School in 1986 and his MBA from ESSEC in Paris in 1988. He is also an alumnus of INSEAD, IMD and MCE executive programs. He is a member of the Management Center Europe Sales & Marketing Council, and he has been a lecturer in pharmaceutical and biotechnology industry seminars and in business schools for several years. Pierre MORGON has over 25 years experience in the pharmaceutical industry, in marketing and operations positions as Product Manager, International Group Product Manager, International Marketing Director, Vice President Marketing, VP Business Unit, General Manager and VP Global Marketing Operations. Through these local and global positions, he has acquired direct experience with blockbuster products in diverse markets (primary care, specialty care, hospital, vaccines, and biotechnology) and many geographies. He spent 2 years at ICI-Pharma, followed by 8 years at Synthelabo, a division of L'Oreal. Subsequently, he joined Aventis Pasteur in 1998, as VP Marketing, International, and was promoted to Vice President Global Product Marketing. Then he had a diversified and complementary set of experiences in operations, first at Yamanouchi Pharma France as General Manager, then at BMS France as Vice President, Hospital Operations, then at Schering-Plough as Director of the Primary Care business unit in France, and eventually at BioAlliance Pharma as Chief Operating Officer and Member of the Management Board. In June 2009, he joined Sanofi Pasteur as Vice President, Franchise & Global Marketing Operations, and was appointed Vice President, Franchise & Global Marketing Strategy in July 2011. He is a member of the Executive Committee. He has been appointed non executive director to the Board of TheraDiag (formerly BioMedical Devices) in March 2012, accompany focusing on in vitro diagnostics in auto-immunity, infectious diseases and allergy.
Blogged on behalf of guest bloggers Milana Shapira and Sophia Doll:
Dr Pierre Morgan from Sanofi Pasteur provided a perspective on the global vaccine market. Profitability from vaccines is unsure into the future as infectious disease targets are running out. Therefore, Morgan envisages a depolarisation in the vaccine world whereby R&D will shift towards therapeutic vaccines, targeting diseases such as cancer or diabetes; this will entail a refocusing towards Western economies. These issues are at hand as innovation is perceived to be slowing down and growth prospects are uncertain. This begs the question as to what the mission and business model of vaccine companies ought to be.
What is your perspective on the global vaccine market? Tell us in the space provided below!
The presentations from the event will be made available from the 1st November.